Bioventus Q4 Earnings Call Highlights [Yahoo! Finance]
Bioventus Inc. - Class A (BVS)
Company Research
Source: Yahoo! Finance
was $37M (+30%) with a 23% margin, and operating cash flow reached a quarterly record of $38M (full-year cash from ops nearly $75M 2026 guidance and targeted investments: Management guided net sales of $600–610M , adjusted EPS of $0.73–0.77 and cash from operations of $82–87M , and plans ˜ $13M of incremental investment in PNS PRP Ultrasonics and international expansion, expecting PNS+PRP to add at least 200 basis points of growth. Product and regional momentum: Pain Treatments led with Q4 growth (DUROLANE/single-injection trend), Surgical Ultrasonics showed progress toward disposables growth, Restorative Therapies fell 26% due to a divestiture but EXOGEN drove ~ organic growth, and international organic growth was ~ Interested in Bioventus Inc.? Here are five stocks we like better. Bioventus (NASDAQ:BVS) executives told investors the company closed 2025 with what leadership described as a “solid quarter” and a “pivotal year,” highlighting stronger organic growth, higher profi
Show less
Read more
Impact Snapshot
Event Time:
BVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVS alerts
High impacting Bioventus Inc. - Class A news events
Weekly update
A roundup of the hottest topics
BVS
News
- Bioventus (BVS) had its price target raised by Barrington Research from $13.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Bioventus (BVS) had its price target raised by Craig Hallum from $15.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics [Seeking Alpha]Seeking Alpha
- Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Bioventus (BVS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
BVS
Earnings
- 3/5/26 - Beat
BVS
Sec Filings
- 3/13/26 - Form 4
- 3/11/26 - Form 144
- 3/5/26 - Form S-8
- BVS's page on the SEC website